| Status | In progress |
| Process | STA 2018 |
| ID number | 1602 |
Project Team
| Project lead | Gemma Barnacle |
Email enquiries
- If you have any queries please email TATeam6@nice.org.uk
| Evidence Review Group / Assessment Group | Southampton Health Technology Assessment Centre (SHTAC), University of Southampton |
Consultees
| Companies sponsors | Jazz Pharmaceuticals (solriamfetol) |
| Others | Department of Health and Social Care |
| NHS England | |
| Welsh Government | |
| Professional groups | Association of British Neurologists |
| British Thoracic Society | |
| Royal College of Physicians | |
| Royal Society of Medicine – Sleep medicine section |
Commentators
| Comparator companies | Accord-UK (methylphenidate) (confidentiality agreement not signed, not participating) |
| Aurobindo Pharma - Milpharm (modafinil) (confidentiality agreement not signed, not participating) | |
| BioProjet (pitolisant hydrochloride) (confidentiality agreement not signed, not participating) | |
| Flynn Pharma (dexamphetamine, methylphenidate) (confidentiality agreement not signed, not participating) | |
| Generics UK T/A Mylan (methylphenidate) (confidentiality agreement not signed, not participating) | |
| Janssen-Cilag (methylphenidate) (confidentiality agreement not signed, not participating) | |
| Martindale Pharma (dexamphetamine) (confidentiality agreement not signed, not participating) | |
| Novartis Pharmaceuticals UK (methylphenidate) (confidentiality agreement not signed, not participating) | |
| Sandoz (methylphenidate,) (confidentiality agreement not signed, not participating) | |
| Shire Pharmaceuticals Limited (methylphenidate) (confidentiality agreement not signed, not participating) | |
| Teva Pharma (modafinil) (confidentiality agreement not signed, not participating) | |
| UCB Pharma (sodium oxybate) (confidentiality agreement not signed, not participating) | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Scottish Medicines Consortium | |
| Welsh Health Specialised Services Committee |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 05 March 2021 - 26 March 2021 | Appraisal consultation |
| 09 February 2021 | Committee meeting |
| 28 October 2020 | In progress. The appraisal committee meeting for this topic has been rescheduled. The technical engagement period for this appraisal is now scheduled to start in early December 2020. The new committee date will be Tuesday 9 February 2021. |
| 05 May 2020 | Schedule affected by COVID-19. Topic update: this appraisal has not been defined as therapeutically critical. The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide an update when this information is available. |
| 02 April 2020 | Topic update: this appraisal has not been defined as therapeutically critical (please follow the link titled rapid guidelines and evidence summaries within the yellow banner at the top of the page for information on recent changes to the way we work). The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide updates as and when this information becomes clear. |
| 28 October 2019 | Please note that the company have requested additional time in order to facilitate a suitably comprehensive and robust evidence submission. NICE have agreed to this and the new deadline for submissions is expected to be early-January 2020. |
| 08 August 2019 | Invitation to participate |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance